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Running title: Talin2 in traction force and invasion 





Talin2, previously presumed to function redundantly with talin1, is indispensable for the 





Talin binds β-integrin tails to activate integrins, regulating cell migration, invasion and 
metastasis.  There are two talin genes, Tln1 and Tln2, encoding talin1 and talin2, respectively.  
While talin1 regulates focal adhesion dynamics, cell migration and invasion, the biological 
function of talin2 is not clear and indeed talin2 has been presumed to function redundantly with 
talin1.  Here we show that talin2 has a much stronger binding to β-integrin tails than talin1.   
Substitution of talin2 Ser339 with Cys significantly decreased its binding to β1-integrin tails to a 
level comparable to that of talin1.  Talin2 localizes at invadopodia and is indispensable for 
traction force and invadopodium-mediated matrix degradation.  Ablation of talin2 suppressed 
traction force generation and invadopodia, which were restored by re-expressing talin2 but not 
talin1.  Furthermore, re-expression of WT talin2 (but not talin2S339C) in talin2-depleted cells 
rescued traction force development and invadopodia.  These results suggest that a strong 
interaction of talin2 with integrins is required to generate traction, which in turn drives 











Talin activates integrin and plays a pivotal role in cell migration, invasion and cancer 
metastasis (Desiniotis and Kyprianou, 2011; Huang et al., 2009; Jin et al., 2015; Tadokoro et al., 
2003).  Talin contains an amino‑terminal globular head domain and a carboxy‑terminal rod 
domain (Goult et al., 2013; Nuckolls et al., 1990).  The talin head domain contains a FERM 
domain, and is responsible for the binding of talin to β-integrin tails (Calderwood et al., 1999). 
The rod domain has several vinculin-binding sites, and two actin-binding sites (Atherton et al., 
2015; Gingras et al., 2005; Hemmings et al., 1996).  The binding of talin to β-integrin tails is 
essential for integrin activation (Calderwood et al., 1999; Tadokoro et al., 2003), which in turn 
regulates focal adhesion (FA) dynamics and invadopodium formation (Bate et al., 2012; Beaty 
et al., 2014; Franco et al., 2004; Nayal et al., 2004), key steps in cell migration and invasion 
(Beaty and Condeelis, 2014; Saykali and El-Sibai, 2014; Webb et al., 2002; Wehrle-Haller, 
2012).  Talin also mediates calpain-induced FA disassembly (Bate et al., 2012; Franco et al., 
2004). Talin1 phosphorylation by Cdk5 regulates FA dynamics, integrin activation, cell 
migration, invasion and metastasis (Huang et al., 2009; Jin et al., 2015).  Talin interacts with 
PIPKIγ, which produces PIP2 to regulate FA dynamics, cell migration and invasion (Chen et al., 
2014; Di Paolo et al., 2002; Li et al., 2013; Ling et al., 2002; Wu et al., 2011).  It recruits the 
moesin-NHE1 complex to modulate pH at invadopodia, consequently governing invadopodium 
stability and matrix degradation (Beaty et al., 2014).  It is also required for the initial generation 
of mechanical force (Giannone et al., 2003; Zhang et al., 2008). 
There are two talin genes, Tln1 and Tln2, encoding talin1 and talin2, respectively.  Talin1 has 
been well studied, while the biological function of talin2 is less clear.  It has been shown that 
talin2 regulates focal adhesion assembly and focal adhesion kinase (FAK) signaling in the 
absence of talin1 (Zhang et al., 2008).  Talin2 is usually localized at large FAs and fibrillar 
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adhesions, whereas talin1 is usually found at smaller FAs in the peripheral region (Praekelt et 
al., 2012; Senetar et al., 2007).  Trastuzumab, a HER2-targeting antibody drug for cancer 
therapy, inhibits cell migration and invasion through down-regulating talin2 (Le et al., 2012).  
Nevertheless, it has been reported that depletion of talin2 does not influence β1-integrin 
activation (Jin et al., 2015).  Thus, it had been presumed that talin2 functions redundantly with 
talin1.  
In the present study, we demonstrate that talin2 functions distinctly from talin1 as a regulator 
of cell invasion.  We show that talin2 has a stronger interaction with β-integrin tails than talin1, 
and that it co-localizes with invadopodia, regulates traction force generation and invadopodium-
mediated matrix degradation.    Furthermore, the strong interaction of talin2 with β-integrin tails 
is essential for the development of strong traction and invadopodia, as substitution of S339 with 
Cys in the talin2 head domain compromises binding to β-integrin tails, and inhibits traction force 
and invadopodium-mediated matrix degradation.  Recently, a disease causing missense variant, 
S339L, of the Tln2 gene was identified as the cause of fifth finger camptodactyly, a digit 
deformity in humans (Deng et al., 2016), which occurred in the presence of talin1, further 
highlighting distinct roles of talin1 and talin2 in development.  This also demonstrates the 
physiological relevance of S339 in talin2 function and the requirement for a robust talin2:integrin 
linkage for normal development.  Thus, interaction of talin2 with integrins is required for traction 
force generation, which in turn drives invadopodium-mediated matrix degradation, and 
ultimately, cancer cell invasion. 
 
Results 
Talin2 binds β-integrin tails stronger than talin1 
To learn whether talin1 and talin2 have any difference in binding to β-integrin tails, CHO-K1 
cells were transfected with EGFP-talin head constructs: EGFP-talin11-433, -talin11-446 or –talin21-
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449, and binding to integrin tails was determined by GST-β integrin tail pull-down assays, using 
GST as a control.  The interaction of talin21-449 with β1A-integrin tail was more efficient than that 
of either talin11-433 or talin11-446   (Fig. 1A).  Similar results were observed with the binding of 
β3A- and β1D-integrin tails (Fig. S1A).  Deletion of the carboxyl terminus of the FERM domain 
enhanced the binding of talin21-449 to β1A tails (Fig. 1B), but reduced the binding of talin11-446 
(Fig. 1C).    The difference between talin1 and talin2 in integrin binding was not caused by other 
associated proteins in the cell lysates, because purified His-tagged talin21-449 binding to β1A-
integrin tail was also stronger than purified talin11-443 and talin11-446 (Fig. 1D).    Thus, the talin2 
head domain (TH2) has a much higher affinity than talin1 head domain (TH1) for β-integrin tails. 
Talin1 C336 and talin2 S339 contribute to the isoform specific affinity differences 
To identify why talin2 binding to integrins is stronger than talin1, we aligned the sequences of 
talin1 and talin2 around the integrin-binding site in F3.  There are several residues that are 
different between the integrin-binding sequences of talin1 and talin2 (Fig. 1E).  Substitution of 
Cys336 of talin1 with Ser enhanced the binding of talin1 to β1A tail to an extent comparable to 
that of talin2 (Fig. 1F), whereas substitution of Ser339 on talin2 with Cys significantly attenuated 
its binding (Fig. 1G).  Substitution of Cys336 on talin1 with other residues dramatically changed 
its binding to β1A tail (Fig. S1B), while mutation at several other mismatching residues had no 
effect on the ability of talin1 binding to integrin tails (data not shown).  The recent finding that 
mutation of Ser339 to Leucine in talin2 has a disease causing phenotype in humans, giving rise 
to the pathology, fifth finger camptodactyly, highlights the physiological importance of this 
residue.  Indeed, a S339L mutant has a similar effect on integrin binding (Fig. 1H).  Similar 
results were observed in pull-down assays using purified His-tagged Tln11-446, Tln21-449 and 
mutants (Fig. 1I).  These data indicate that Ser339 plays a significant role in the high integrin 
binding ability of talin2.   
Talin2 is essential for the assembly of large, stable FAs and traction force generation 
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To ascertain whether talin2 is different from talin1 in regulating FAs, we used CRISPR/Cas9 
to knockout talin1 or talin2 from U2 OS cells.  Ablation of talin isoforms was achieved by 
infecting the cells with lentiviruses that express Cas9 and talin1 or talin2 gRNAs (Fig. 2A).  The 
talin1- or talin2-null cells were plated on fibronectin and stained for zyxin and either talin1 or 
talin2, using cells expressing empty LentiCRISPR v2 vector as a control.   Ablation of either 
talin1 or talin2 inhibited the assembly of small FAs (<7 µm2), as determined by Zyxin staining 
(Fig. 2B&C). However, ablation of talin1 did not influence large FAs (>10 µm2), whereas talin2 
KO significantly diminished the formation of large FAs (Fig. 2C, bottom panel).  Similar results 
were observed in cells where talin1- or talin2 were depleted using shRNAs (Fig. S2A, B&C).  In 
the central regions (>5 µm from edges) of U2 OS cells, large spots of talin2 were more visible 
than those of talin1 (Fig. 2D).   Likewise, in MDA-MB-231 and MDA-MB-435S cancer cells, 
talin1 was usually found in smaller FAs, whereas talin2 formed larger FAs (Fig. S2D&E).  
However, although ablation of talin1 also suppressed the assembly of FAK to small FAs (<7 
µm2), ablation of talin2 had little effect on FAK localization (Fig. 2E&F).     These results suggest 
that talin2 is mainly responsible for large, stable FA assembly, while talin1 mediates smaller FA 
formation. 
To compare the roles of talin1 and talin2 in traction force generation, talin1- or talin2-ablated 
U2 OS cells were plated on fibronectin-conjugated polyacrylamide gels containing Red 
FluoSpheres, using cells carrying empty CRISPR vector as a control.  Traction force was 
measured using a Nikon A1 confocal microscope equipped with a CO2 incubator system, and 
analyzed using the method of Butler et al. (Butler et al., 2002).   Either talin1 or talin2 knockout 
(KO) significantly inhibited the traction force (Fig. 3A&C).  Talin1 KO also significantly 
depressed the cell spreading on the polyacrylamide gel, whereas talin2 KO had only marginal 
effects (Fig. 3B), suggesting that the effect of talin1 KO on traction force may be caused by its 
suppression of cell spreading.    
7 
 
Since talin1 head domain (TH1) has been reported to mediate cell spreading in talin1-KO 
cells (Zhang et al., 2008), we examined whether transfection of TH1 could rescue the traction 
force production in talin1-null cells.  Talin1-null U2 OS cells were transfected with EGFP-TH1 
(talin11-446) and –TH2 (talin21-449), respectively (Fig. 4A).  The cells were plated on 
polyacrylamide gels containing Red FluoSpheres for cell spreading and traction force assays, 
using talin1-KO cells as a control.   Transfection of talin1-KO cells with TH1 significantly rescued 
the cell spreading defect, while transfection with TH2 had no effect (Fig. 4B&C).  TH1-mediated 
cell spreading was accompanied by an increase in traction force, while TH2 was unable to 
rescue the cell spreading and traction force defect caused by talin1 ablation (Fig. 4B&D).   
Since the talin head domain lacks the major actin-binding site (Atherton et al., 2015), it is 
deficient in mediating traction force production.  These results suggest that the apparent role of 
talin1 in traction force is partially caused by its effect on cell spreading.     
To explore whether talin2 is dispensable in traction force generation, talin2-KO U2 OS cells 
were transfected with full-length (FL) pEGFP-talin1 or –talin2 (Fig. 4E) and the traction force in 
these cells were determined, using talin2-KO cells and CRISPR vector cells as controls.   
Transfection with talin1 caused only a slight increase in traction force, whereas transfection with 
talin2 almost restored the traction force to the levels of CRISPR control cells (Fig. 4F).  The role 
of talin2 in traction force production is further supported by shRNA knockdown experiments, 
where depletion of talin2 caused significant reduction in traction force production in U2 OS cells 
and MDA-MB-231 cells (Figure S3).  These results indicate that talin2 is indispensable for 
cellular traction force generation.   
Strong binding of talin2 to integrins is essential for the development of traction force 
To stably express full-length talin2WT and talin2S339C in talin2-null U2 OS cells, pAAVS1-
EGFP-talin2WT or –talin2S339C were co-transfected with AAVS1 gRNA into talin2-null U2 OS 
cells.  The cells were selected with neomycin and sorted for EGFP positive cells.  The 
expression of EGFP-talin2WT and –talin2S339C was examined by Western blotting (Fig. 5A).  To 
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examine whether the strong binding of talin2 to β-integrins is essential for traction force 
generation, talin2-null cells that express EGFP-talin2WT or –talin2S339C were plated on the 
gelatin-conjugated polyacrylamide gels containing Red FluoSpheres, and traction force was 
measured using talin2-null cells and CRISPR vector cells as controls.  Expression of EGFP-
talin2WT in talin2-null cells restored more than 70% of traction force, whereas that of EGFP-
talin2S339C, which has reduced affinity to β-integrins, had little effect (Fig. 5B&C).  This result 
suggests that a strong binding of talin2 to β-integrins is required for traction force generation.  
Strong binding of talin2 to integrins is required for cell invasion 
To examine the role of talin1 and talin2 in cell invasion, talin1- or talin2-ablated U2 OS cells 
were examined for their capacities to penetrate through transwell filters coated with Matrigel.  As 
shown in Fig. 6A&B, ablation of either talin1 or talin2 inhibited the invasion of U2 OS cells.  
Talin1 or talin2 KO caused approximately 77-91% inhibition of U2 OS cell invasion. This critical 
role of talin1 and talin2 in cell invasion was also observed in MDA-MB-231 cells (Fig. 6C).   
These results indicate that both talin1 and talin2 play critical roles in cell invasion. 
To determine the essential role of the talin2-β-integrin interaction in cell invasion, talin2-null 
U2 OS cells that express EGFP-talin2WT or –talin2S339C were tested for their invasive capacities 
toward Matrigel, using talin2-null cells and CRISPR vector cells as controls.   Expression of 
EGFP-talin2WT in talin2-null cells significantly rescued the cell invasion, whereas that of EGFP-
talin2S339C, had only slight effect (Fig. 6D&E), suggesting that strong binding of talin2 to integrins 
is required for cell invasion. 
Talin2 co-localizes with invadopodia and regulates matrix degradation  
To examine the co-localization of talin2 with invadopodia, U2 OS cells were plated on Cy3-
labeled gelatin that was immobilized on glass-bottom dishes, and co-stained for talin2 and a 
invadopodium marker, cortactin or Tks5.  Talin2 significantly co-localized with cortactin and 
Tks5 at either large or small degradation holes (Fig. 7A&B).  More than 80% of invadopodia co-
localized with talin2.   MDA-MB-231 cells had more robust invadopodia, where talin2 co-
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localized with cortactin, as compared to U2 OS cells (Fig. 7C).  Talin1 also co-localized with 
invadopodia in MDA-MB-231 cells (Supplementary Fig. S4A).   We then examined the co-
localization of talin2 with two other invadopodium markers, β1-integrin and N-WASP.  The β1-
integrin and talin2 co-localized with degradation holes in U2 OS cells, whereas β1-integrin at 
FAs did not (Supplementary Fig. S4B).  Talin2 also co-localized with N-WASP at invadopodia-
like structures (Supplementary Fig. S4C). These results suggest that talin2 is a marker for 
invadopodia. 
To determine the roles of talin1 and talin2 in invadopodia, talin1 or talin2-ablated U2 OS 
cells were plated on Alexa488-labeled gelatin and stained for filamentous actin.  Although 
ablation of either talin1 or talin2 dramatically inhibited invadopodium-mediated matrix 
degradation, talin2 KO had slightly more severe effect on invadopodia than talin1 KO (Fig. 
7D&E), suggesting a key role of talin2 in invadopodium regulation.  
To examine whether talin2 is indispensable for invadopodium-mediated matrix degradation, 
talin2-KO U2 OS cells were transfected with full-length pEGFP-talin1 or -talin2, and the matrix 
degradation in these cells were determined, using talin2-KO and CRISPR vector cells as 
controls.   Transfection with talin1 did not significantly improve invadopodial matrix degradation, 
whereas transfection with talin2 rescued the invadopodia in talin2-KO cells (Fig. 7F&G).  Using 
shRNA to deplete talin2 also caused significant reduction in invadopodium formation in U2 OS 
cells (Figure S4E).  However, talin2 KO did not affect the invadopodium-like staining of cortactin 
(Fig. S4D). These results suggest that talin2 is indispensable for invadopodium-mediated matrix 
degradation.  
Talin2-mediated traction force drives invadopodium-mediated matrix degradation 
To learn whether the traction force distribution is co-localized with invadopodia, U2 OS cells 
were plated on Alexa488-gelatin-conjugated polyacrylamide gels containing Red FluoSpheres.  
Invadopodia and traction force were measured simultaneously using a Nikon A1 confocal 
microscope.  As shown in Fig. 8A&B, traction force was co-localized with approximately 65% of 
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degraded holes of invadopodia, suggesting that traction force may regulate invadopodium-
mediated matrix degradation. 
To examine whether talin2-mediated traction force regulates invadopodium-mediated matrix 
degradation, talin2-null U2 OS cells that stably express EGFP-talin2WT or –talin2S339C were 
plated on glass-bottom dishes immobilized with Cy3-gelatin, using talin2-KO cells and CRISPR 
vector cells as controls.   Talin2WT formed invadopodium-like structures, whereas talin2S339C was 
deficient to do so (Fig. 8C&D).  Expression of talin2WT in talin2-null cells completely restored 
invadopodium-mediated matrix degradation, whereas expression of talin2S339C, which is deficient 
in traction force, did not (Fig. 8E).   
To test the role of talin2-mediated traction force in invadopodia in another cell line, talin2 in 
MDA-MB-231 cells was ablated by infecting the cells with lentiviruses that express Cas9 and 
talin2 gRNAs.  AAVS1 gRNA were co-transfected with pAAVS1-EGFP-talin2WT and pAAVS1-
EGFP–talin2S339C, respectively, into talin2-null cells.  The expression of EGFP-talin2WT and 
EGFP-talin2S339C in talin2-null MDA-MB-231 cells was detected using an anti-talin2 antibody 
(Fig. 8F).  Similar to the results observed in U2 OS cells, talin2WT markedly restored the 
invadopodia in talin2-null MDA-MB231 cells, whereas talin2S339C had little effect (Fig. 8G&H).  
Thus, talin2-mediated traction force might regulate invadopodium-mediated matrix degradation. 
 
Discussion 
In invasive cells, talin2 generates strong traction force through its high affinity to β-integrins, 
driving invadopodium-mediated matrix degradation and ultimately, cell invasion (Fig. 8I).  Thus, 
talin2 binding to β-integrin tails is indispensable for cancer cell invasion.     
We found that talin2 binds integrin tails stronger than talin1 does and that talin2 S339 
contributes to its strong interaction with β-integrins.  Substitution of S339 with Cys caused a 
reduction in its binding to integrins, whereas the reciprocal mutation of talin1 C336 to Ser 
enhanced talin1 binding (Fig. 1).   Our data are different from the results of a previous report 
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(Anthis et al., 2009), where the F3 domains of talin1 and talin2 bound to β1A tails with Kd of 491 
and 652 μM, respectively, as measured by NMR.  In our study, we found that talin2 had a 
stronger interaction with β-integrin tails than talin1; this discrepancy is probably because we 
used the full-length talin2 head domain while the F3 domain alone was used in Anthis’ 
experiments.  Indeed, the talin2 head domain bound to β1A tails much more efficiently than the 
F2-F3 domain (Fig. S1C).  This is consistent with a previous report (Calderwood et al., 1999).   
The discrepancy could be also caused by the different buffers used in the assays, where we 
included 3 mg/ml BSA or 0.5 mg/ml gelatin in our binding buffer to reduce non-specific binding.  
Our findings provide a molecular basis to explain the different roles of talin1 and talin2.  
Talin1 and talin2 have distinct roles in regulating FA assembly.  Based on FAK and Zyxin 
staining, talin1 knockout or knockdown inhibited small FAs (<7 μm2), but had no effect on large 
FAs (>7 μm2) (Fig. 2; Fig. S2).  Talin2 knockout or knockdown also suppressed Zyxin localizing 
to FAs, but did not influence the recruitment of FAK to FAs.   These results are consistent with 
previous findings obtained in talin-1 knockout cells (Zhang et al., 2008).   Since Zyxin is a 
marker for FA maturation (Zaidel-Bar et al., 2003), these results suggest that talin1 regulates 
small FA assembly, whereas talin2 controls larger, more stable FA formation.  Talin1-mediated 
smaller FAs may contribute to FA dynamics and cell migration (Huang et al., 2009), whereas the 
property of talin2 to aggregate into large assemblies may stabilize invadopodia.  
 
We found that talin2 played an important role in traction force generation.  Either talin2 KO or 
KD suppressed traction force generation (Fig. 3; Fig. S3).  Moreover, the traction force in talin2-
KO cells can be rescued by transfecting with talin2, but not with talin1, indicating the 
indispensable role of talin2 in traction force generation (Fig. 4).   Furthermore, talin2-mediated 
traction force is dependent on its strong interaction with integrin tails (Fig. 5).  Talin2-mediated 
traction force generation could be related to the role of talin2 in large FA formation, because 
FAs regulate traction force generation (Dumbauld et al., 2013; Hinz and Gabbiani, 2003; 
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Morimatsu et al., 2015).  Ablation of talin1 caused a reduction in traction force, but this effect 
can be partially attributed to the role of talin1 in cell spreading (Figs. 3 and 4), because: 1) 
talin1 KO also inhibited cell spreading (Fig. 3); 2) expression of the talin1 head domain in talin1 
null cells promoted spreading and traction force generation (Fig. 4).  The talin1 head domain 
retains the integrin activation function of talin1, thus promoting cell spreading (Calderwood et 
al., 1999; Zhang et al., 2008).  However, it lacks the major actin binding site and is deficient in 
mediating traction force (Zhang et al., 2008).   The distinct roles of talin1 and talin2 in cell 
spreading and traction force could be caused by their different binding affinities toward β-
integrins.   This assertion is supported by the deficiency of talin2S339C in mediating traction force 
(Fig. 5).   It is possible that the different mechanical properties between talin1 and talin2 rod 
domains may contribute to traction force generation (Austen et al., 2015).  Taken together, it is 
likely that talin1 indirectly modulates traction force through promoting cell spreading, whereas 
talin2 may directly control traction force by acting as a mechanical transmitter between integrins 
and the actin cytoskeleton.  
Although it has been reported that talin2 is not essential for fibroblast migration (Debrand et 
al., 2012) , we demonstrate that it plays an important role in cell invasion.   Either talin2 KO or 
KD inhibited cancer cell invasion (Fig. 6).  Furthermore, re-expression of talin2WT in talin2-null 
cells rescued cell invasion, whereas re-expression of talin2S339C, which is deficient in β integrin-
binding, did not (Fig. 6).  The role of talin2 in cell invasion can be attributed to its effect on 
invadopodium-mediated matrix degradation, a key regulatory point for cell invasion (Beaty and 
Condeelis, 2014; Bergman et al., 2014; Paz et al., 2014; Weaver, 2006; Yamaguchi et al., 
2006).    
Invadopodia are large assemblies that mediate cell invasion (Beaty and Condeelis, 2014; 
Paz et al., 2014; Revach and Geiger, 2013).  We found that talin2 considerably co-localized with 
invadopodia (Fig. 7).  In fact, large and round talin2 staining spots usually co-localized with 
invadopodia.   Ablation of either talin1 or talin2 reduced invadopodium-mediated matrix 
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degradation, but ablation of talin2 had slightly more effects than that of talin1 (Fig. 7).  
Furthermore, expression of full-length talin2WT rescued invadopodium-mediated matrix 
degradation in talin2-null cells, whereas expression of talin2S339C, which has reduced binding to 
β1-integrin tails, had little effect (Fig. 8).  These results suggest that a strong interaction 
between talin2 and β-integrin tails is indispensable for invadopodium-mediated matrix 
degradation. 
Interestingly, regions of high traction forces also co-localized with invadopodia (Fig. 8A).  Re-
expression of talin2WT but not talin2S339C in talin2-null cells restored the traction force generation 
and invadopodium-mediated matrix degradation (Fig. 5; Fig. 8). These results suggest that 
binding of talin2 to β-integrin tails is essential for the generation of traction force, which in turn 
drives invadopodium-mediated matrix degradation and cancer cell invasion.   
It has been reported that podosomes, similar structures to invadopodia, develop in the 
absence of traction force (Yu et al., 2013).  We found here that talin2-mediated traction force 
was required for invadopodium-mediated matrix degradation. However, talin2 seems not to be 
required for the initial development of invadopodia, because talin2 KO did not influence the 
assembly of cortactin, an invadopodium marker, into invadopodium-like structures (Fig. S4).  
Thus, talin2-mediated traction force may instead regulate invadopodium stability or maturation.  
Although we still do not understand how traction force regulates invadopodia, our findings fill in 
the gaps of our existing knowledge of talin2 and uncover novel but fundamental roles of talin2 in 
mediating traction force and invadopodium development during cell invasion.   
Talin1 is generally thought to play more important roles in cell migration and embryogenesis: 
talin1 knockout causes embryonic lethality in mice (Monkley et al., 2000), whereas  talin2 is not 
essential for mouse embryonic development (Debrand et al., 2012).  However, as we show 
here, talin2 generates traction force to mediate invadopodium formation and cell invasion.  The 
recent identification of a human pathology arising from a missense variant, S339L, of the Tln2 
gene resulting in the digit deformity, fifth finger camptodactyly (Deng et al., 2016), demonstrates 
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the physiological importance of S339 in talin2 function and the requirement for a robust 
talin2:integrin linkage for normal development.  Both an S339C and the disease copying S339L 
mutant reduced the affinity of talin2 for integrin and the ability of cells to generate traction 
forces. It is possible that the deleterious effect of this mutation on integrin binding and traction 
force generation may be the cause of the developmental abnormality.  Interestingly, talin2 was 
found to be down-regulated by trastuzumab, a HER2-targeting antibody drug for breast cancers 
(Le et al., 2012).  Thus, inhibition of talin2 function could be a potential strategy for cancer 
therapy.   
 
Materials and methods 
Reagents 
Anti-talin1 (clone 97H6) and anti-talin2 (clone 53.8) antibodies were from AbD Serotec.  Anti-
zyxin (clone EPR4302) rabbit monoclonal antibody was from Abcam.   Anti-cortactin mouse 
monoclonal antibody (clone 4F11) and anti-Tks5 rabbit polyclonal antibody (SH3 #4) were from 
EMD Millipore.  Anti-cortactin (H222) rabbit polyclonal and anti-N-WASP (clone 30D10) rabbit 
monoclonal antibodies were from Cell Signaling Technology.  Anti-β1-integrin monoclonal 
antibody (P5D2) was from R&D Systems.  Anti-FAK[pY397] (clone 18/FAK (pY397)) was from 
BD Biosciences.  Anti-talin2 (GW22654) chicken polyclonal and anti-tubulin (clone B-5-1-2) 
monoclonal antibodies bovine skin gelatin and pLKO1 lentivirus shRNAs that respectively target 
talin1 and talin2 were from Sigma. Talin1 shRNA clones are TRCN0000123105 (#1), 
TRCN0000299020 (#2).  Talin2 shRNA clones are TRCN0000122990 (#1) and 
TRCN0000122992 (#2).  LentiCRISPRv2 and pSpCas9(BB)-2A-Puro V2.0, which were 
generated by Feng Zhang’s Lab (Ran et al., 2013), were from Addgene.  Alexa488-labeled 
gelatin and Red FluoSpheres were from Life Technologies.  Cy3 dye was from Click Chemistry 
Tools.  Gelatin was labeled with Cy3 according to the manufacturer’s instruction.  DyLight 488 
conjugated goat anti-mouse IgG (H+L) and Alexa Fluor 488 labeled goat anti-chicken IgY (H+L) 
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were from Thermo Scientific.  Dylight 550 or 633 labeled goat anti-mouse and anti-rabbit IgG 
(H+L) were from Immunoreagents (Raleigh, NC).  anti-Fibronectin and recombinant human EGF 
were from Akron Biotech; Growth factor reduced Matrigel was from BD Bioscience. Pfu Ultra 
was from Agilent Technologies.  Cold Fusion Cloning Kit was from System Biosciences (Palo 
Alto, CA).  Anti-GFP monoclonal antibody and Safectine RU50 transfection kit were purchased 
from Syd Labs (Malden, MA).  DNA primers were synthesized by Integrated DNA Technologies.  
Plasmid construction 
The full-length pEGFP-talin2 WT  was subcloned by the following steps: 1) DNA fragments 
encoding residues 1-1159 of human talin2 were amplified by Pfu Ultra-based PCR using human 
talin2 cDNA clone as template and 5’-atg cac tcg agc tat ggt ggc cct gtc ctt aaa gat ttgt-3’ / 5’-
act gag gta ccg tct cga gca gaa tct aac atg gca t-3’ as primers and subcloned into pEGFP-C1 
via Xho1/Kpn1 sites; 2) fragments encoding residues 1160-2543 of talin2 were amplified using 
human cDNA from U2 OS cells and 5’-ggc tgc atc gac aac cga ccc c-3’/5’-tat tat cta gat tag ccc 
tca tct tcc ctc agc tc-3’ and subcloned into the resulted plasmid in step 1 via Not1/Xba1 sites.  
pEGFP-talin21-449 was generated by amplifying DNA fragments encoding residues 1-449 using 
5’-atg cac tcg agc tat ggt ggc cct gtc ctt aaa gat ttg t-3’ / 5’-ggg ccc gtc gac tat gag ccg tgc tct 
gcc ttc cc-3’ as primers and subcloning into pEGFP-C1 vector via Xho1/Sal1 sites.  pEGFP-
talin11-446 was generated by amplifying DNA fragments encoding residues 1-446 using 5’-ggg 
ccc gaa ttc tat ggt tgc act ttc act gaa gat cag-3’ / 5’-ggg ccc gtc gac tta aga gcc atg ctc cac ttt 
ccc c-3’ as primers and subcloning into pEGFP-C1 vector via EcoR1/Sal1 sites. pEGFP-talin21-
449
S339C
 was created by pfu Ultra-based PCR using pEGFP-talin21-449 as template and 5’-gga tca 
cca aag act gtg tga tgc gcg tgg-3’ / 5’-cca cgc gca tca cac agt ctt tgg tga tcc-3’ as primers.  
pEGFP-talin11-446C336S was created by PCR using pEGFP-talin11-446 as template and 5’-cat cac 
caa gga gag tgt gat gcg ag-3’ / 5’- ctc gca tca cac tct cct tgg tga tg -3’ as primers. pEGFP-
talin11-433 was reported previously (Huang et al., 2009).  pQE-talin11-446 and -talin21-449 were 
generated by amplifying the DNA fragments using 5’-ggg ccc gag ctc atg gtt gca ctt tca ctg aag 
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atc ag-3’/5’-ggg ccc gtc gac tta aga gcc atg ctc cac ttt ccc c-3’ and 5’-atg cag aat cca tgg tgg ccc 
tgt cct taa aga ttt gt-3’/5’-ggg ccc gtc gac tat gag ccg tgc tct gcc ttc cc-3’ as primers and 
subcloning into pQE-30 vector via Sac1/Sal1 and BamH1/Sal1, respectively.  The rescue 
plasmids pEGFP-talin21-449-R and pEGFP-talin21-449S339C-R were created by PCR using pEGFP-
talin21-449 as template and 5’-gtg aag acc atg cag ttc gag cca tct aca gct gt-3’ / 5’-aca gct gta gat 
ggc tcg aac tgc atg gtc ttc ac-3’ as primers.  The full-length rescue plasmids pEGFP-talin2-R 
and pEGFP-talin2S339C-R were created by digesting full-length pEGFP-talin2 with BsrG1/EcoRV 
and ligating the resulting larger fragment with the smaller fragments from the rescue plasmids 
pEGFP-talin21-449-R and pEGFP-talin21-449S339C-R.  The full-length pAAVS1-EGFP-talin2 and 
pAAVS1-EGFP-talin2S339C were created by subcloning talin2 and the mutant into pAAVS1-
EGFP vector, using the same strategy as used to subclone full-length pEGFP-talin2.   The 
pAAVS1-EGFP vector was generated by the following procedures: 1)pEGFP-C1 with BsiWI (at 
nt 20) and AscI (at nt 3533) was created by sequential PCR using pEGFP-C1 as template and 
5’-gtt att aat agt aat cac gta cgg ggt cat tag ttc ata g-3’ / 5’-cta tga act aat gac ccc gta cgt gat tac 
tat taa taa c-3’ and 5’-cgg aat cgt ttt ccg gcg cgc cgg ctg gat gat c-3’ / 5’-gat cat cca gcc ggc gcg 
ccg gaa aac gat tcc g-3’ as primers; 2) the left and right homologous arms of AAVS1 were 
amplified by PCR using 5’-tta ata gta atc acg tac gtg ctt tct ctg acc agc att c-3’ / 5’-atg aac taa 
tga ccc cgt acg gcc cca ctg tgg ggt gga-3’ and  5’-cgg aat cgt ttt ccg gcg cgc cac tag gga cag gat 
tgg tg-3’ / 5’-gga tca tcc agc cgg cgc gcc aga gca gag cca gga acc c-3’ as primers,  and 
subcloned into the modified pEGFP-C1 vector via BsiWI and AscI, respectively, using the Cold 
Fusion Cloning Kit.  AAVS1 gRNA was generated by annealing oligos 5’-cac cgc tag tgg ccc cac 
tgt ggg g-3’ / 5’-aaa ccc cca cag tgg ggc cac tag c-3’ and subcloning into BbsI–digested 
pSpCas9(BB)-2A-Puro V2.0 vector.  LentiCRISPR-TLN1 was created by annealing oligos 5’-cac 
cgg gat ccg ctc acg aat gat g-3’ / 5’-aaa cca tca ttc gtg agc gga tcc c-3’ and subcloning into 
BsmB1-digested lentiCRISPRv2 vector.  LentiCRISPR-TLN2 was generated by annealing oligos 
5’-cac cgc gtg tcg agt cat tcg gga a-3’ / 5’-aaa ctt ccc gaa tga ctc gac acg c-3’ and subcloning 
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into lentiCRISPRv2 vector. All plasmids were sequenced by Eurofins MWG Operon (Huntsville, 
AL). 
Cell culture and transfection  CHO-K1 Chinese hamster ovary cells, MDA-MB-231 human 
breast cancer cells, U2 OS human bone osteosarcoma cells and 293T human embryonic kidney 
cells were from the American Type Culture Collection and were maintained in DMEM medium 
(Corning Inc.) containing 10% fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin 
(100 µg/ml).  CHO-K1 and 293T cells were transfected with Safectine RU50 according to the 
manufacturer’s protocol.  U2 OS cells were transfected with Mirus Ingenio solution using 
GenePulser Xcell (Bio-Rad Inc., Hercules, CA).   
Tln1 and Tln2 KO by CRISPR   Preparation of viruses and cell infection were performed as 
described previously (Li et al., 2013; Wu et al., 2011). LentiCRISPR-TLN1 and lentiCRISPR-
TLN2 were co-transfected with packaging vectors pMDLg/pRRE, pRSV-Rev and CMV-VSVG 
into 293FT cells.  Lentiviral particles were collected and used to infect U2 OS cells.  The cells 
were selected with puromycin and clones isolated.  Tln1 or Tln2 KO clones were detected by 
Western blotting using anti-talin1 and anti-talin2 monoclonal antibodies. 
Re-expression of talin2 and talin2S339C in talin2 null cells  The AAVS1 gRNA was co-
transfected with pAAVS1-EGFP-talin2WT and -EGFP-talin2S339C, into talin2 null cells.   
Transfected cells were selected with neomycin.  EGFP-positive cells were sorted by flow 
cytometry, or EGFP-positive clones were isolated.   
Protein interaction assays   CHO-K1 cells were transfected with pEGFP-talin11-433, -talin11-446, 
-talin11-449, or their mutants.  At 28 h post-transfection, the cells were harvested in lysis buffer A 
(50 mM Tris-HCl pH 7.4, 1% NP‑40, 150 mM NaCl, 1 mM EDTA and a protease inhibitor 
cocktail).  Cell lysates were cleared by centrifugation and incubated with glutathione–Sepharose 
beads loaded with GST or GST-β-integrin tails at 4 °C for 2 h.  The beads were washed with the 
lysis buffer 4 times and resuspended in SDS-sample buffer. Samples were analyzed using 
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SDS–PAGE and transferred to nitrocellulose membrane for the detection of interacting proteins.   
The binding of purified His-tagged proteins to GST-β-integrin tails was performed in lysis Buffer 
A containing 3 mg/ml BSA (Fig. 1D) or 0.5 mg/ml gelatin (Fig. 1I). 
Cell invasion assays  Cell invasion was performed as described previously (Li et al., 2013).  
Briefly, 100 µl of Matrigel (1:30 dilution in serum-free DMEM medium) was added to each 
Transwell polycarbonate filter and incubated at 37 °C for 5 h.  Cells were trypsinized and 
washed 3 times with DMEM containing 1% FBS.  The cells were resuspended in DMEM 
containing 1% FBS at a density of 5×105 cells/ml.  The cell suspensions (100 µl) were seeded 
into the upper chambers, and 600 µl of DMEM medium containing 1% FBS, 20 ng/ml EGF and 
10 µg/ml fibronectin were added to the lower chambers.  The cells were allowed to invade for 12 
h (or as indicated) in a CO2 incubator, fixed, stained and quantitated as described previously 
(Wu et al., 2011). 
Traction force measurement   Glass-bottom dishes were silanized by 0.5% silane, and 
activated by 0.5% glutaraldehyde. A drop of gel solution containing acrylamide (6%), bis-
acrylamide (0.75%), ammonium persulfate (APS), TEMED, and FluoSpheres® carboxylate-
modified beads (diameter 0.2 μm, 1:85 dilution by volume) was added to the dishes and 
covered by a coverslip. The coverslip was removed, and gels were activated with sulfo-
SANPAH under UVA exposure and then conjugated with gelatin (0.2 mg/ml).  Cells were plated 
on the gels and traction force was measured as described previously (Butler et al., 2002), using 
an A1 confocal microscope in Lexington VA Medical Center. 
Invadopodium assays Glass-bottom dishes were coated with 100 μl of warm Alexa488-
conjugated gelatin (0.2 mg/ml) in PBS containing 2% sucrose.  The coated dishes were dried, 
fixed with pre-chilled glutaraldehyde solution (0.5% in PBS), washed with PBS and then 
reduced with 5 mg/ml of sodium borohydride in PBS.    The dishes were washed extensively 
with PBS and then incubated with DMEM containing 10% FBS and antibiotics for 1h.  Cells 
were plated at low density to the dishes and cultured for 24h, fixed with paraformaldehyde and 
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stained for talin2 (or talin1) and F-actin.  Images were acquired using a TIRF microscope.  To 
measure invadopodium areas, the images were converted to 16 bit inverted JPEG format 
(invadopodia are white spots) using ImageJ. The images were then opened with NIS Elements, 
thresholded (invadopodium spots were precisely covered by red).  A Region-Of-Interests (ROIs) 
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Figure 1. Talin2 has a much higher affinity to β-integrin tails than talin1.  A-C. Binding of 
talin truncated mutants to β1A-integrin tails measured by GST pull-down assays.  The EGFP 
fusion proteins of talin mutants were transiently expressed in CHO-K1 cells.  A. Binding of 
EGFP-talin11-433, -talin11-446, and -talin21-449.  B. Binding of EGFP-talin11-446, -talin21-449, -talin21-
23 
 
403 and –talin2389-449.  C. Binding of EGFP-talin11-446, -talin11-401, -talin1395-446 and -talin21-449.  D. 
Interaction of purified His-tagged-talin11-446 and -talin21-449 to immobilized GST and GST-β1A 
tails.  The binding was detected by Coomassie staining.    E. Sequence alignment of the 
integrin-binding region of the F3 domains of talin1 and talin2.  C336 in talin1 and S339 in talin2 
are shown in red.  F-H. The EGFP fusion proteins of talin mutants were transiently expressed in 
CHO-K1 cells.  The binding of talin mutants to β1A-integrin tails was determined by GST-pull-
down assays. F. Substitution of talin1 C336 with Ser promoted its binding to β1A-integrin tails.  
G. Substitution of talin2 S339 with Cys reduced its binding to β1A integrin tails.  H. Substitution 
of talin2 S339 with Leu diminished its binding to β1A integrin tails.  I. Binding of purified His-
tagged-talin11-446, -talin11-446C336S, -talin21-449, and talin21-449S339C to immobilized GST and GST-
β1A tails.  Binding was detected by Coomassie staining. 
 
Figure. 2. Talin1 is required for small FA formation, whereas talin2 is responsible for 
large, stable FA assembly.  A. Endogenous talin1 and talin2 in CRISPR vector-transfected U2 
OS cells and talin1 or talin2-null U2 OS cells.  B. The distribution of Zyxin and talin1 (top) or 
talin2 (bottom) in talin1- or talin2-null cells.  Talin1 or talin2-null U2 OS cells were plated on 
fibronectin (5 μg/ml)-coated glass-bottom dishes for 4 h, fixed and co-stained for talin1 (or talin2 
) and Zyxin.   Images were acquired by TIRF microscopy.  Scale bar, 20 μm.  C. Area 
distribution of Zyxin staining in talin1- (top) and talin2- (middle)-null U2 OS cells.   The small 
graph in the bottom highlights the different effects of talin1 or talin2 KO on large (>10 µm2) FAs.  
Data are mean ± SEM of 3 experiments.  In each experiment, FAs of 20 cells from each group 
were analyzed and plotted.  t-test, *P<0.05, **P<0.01, ***P < 0.001.  D. Area distribution of 
talin1 and talin2 staining in central parts (5 µm from edges) of cells.  Data are mean ± SEM of 3 
experiments.  t-test, *P<0.05.  E. The distribution of FAK[pY397] in talin1- or talin2-null cells.  
Talin1 or talin2-null U2 OS cells were cultured on fibronectin, fixed and stained for FAK[pY397].  
Scale bar, 20 μm.  F. Area distribution of FAK[pY397] staining in talin1- (left) and talin2- (right)-
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null U2 OS cells.   Data are mean of 2 experiments.  In each experiment, FAs of 20 cells from 
each group were analyzed and plotted. 
Figure 3. The roles of talin1 and talin2 in cell spreading and traction force production.  A.  
Effects of talin1 and talin2 KO on cell spreading and traction force generation in U2 OS cells.  
Scale bar, 30 µm.  B. Quantitative cell spreading area in talin1- or talin2-ablated U2 OS cells, 
using cells carrying CRISPR vector as a control.  Data are presented as mean ± SEM of 3 
experiments.  In each experiment, 30 cells from each group were analyzed.  t-test, *P < 0.05, 
***P < 0.001.  C. Quantitative constrained traction force in talin1- or talin2-ablated U2 OS cells, 
using cells carrying CRISPR vector as a control.  Data are presented as mean ± SEM of 3 
independent experiments.  t-test, ***P < 0.001. 
Figure 4. Talin2 is indispensable for traction force generation.     A. Expression of EGFP- 
talin1 head domain (TH1) and -talin2 head domain (TH2) in talin1-KO U2 OS cells.  B-D.  
Expression of TH1 but not TH2 partially rescued the cell spreading and traction force defect 
caused by talin1-KO.  B. Talin1-KO U2OS cells were transiently transfected with EGFP-TH1 or 
TH2, and cultured on polyacrylamide gel containing Red FluoSpheres for determining the cell 
spreading and traction force, using CRISPR vector-infected cells and talin1-KO cells as 
controls.  Scale bar, 30 µm.  C. Quantitative cell spreading areas on polyacrylamide gel.  Data 
are presented as mean ± SEM of 3 experiments.  In each experiment, 30 cells from each group 
were analyzed. t-test, **P<0.01.  D. Quantitative constrained traction force.  Data are presented 
as mean ± SEM of 3 independent experiments. In each experiment, more than 30 cells from 
each group were analyzed.  t-test, **P<0.01.  E. Transient expression of full-length EGFP-talin1 
and -talin2 in talin2-KO U2 OS cells.  F.  Re-expression of full-length EGFP-talin2 rescued the 
traction force defect caused by talin2 KO, whereas re-expression of talin1 only induced slight 
increase in traction force.  Data are presented as mean ± SEM of 4 experiments. In each 
experiment, more than 40 cells from each group were analyzed.  t-test,*P<0.05, ***P<0.001.   
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Figure 5. Strong binding of talin2 to β-integrin tails is required for traction force 
generation.   A. Stable expression of EGFP-talin2WT and -talin2S339C in talin2-null U2 OS cells 
using CRISPR.  B-C. Re-expression of talin2WT in talin2-null cells restored their traction force 
generation, but that of talin2S339C did not.  B. Talin2-null U2 OS cells that express EGFP-talin2WT 
or –talin2S339C were cultured on polyacrylamide gel containing Red FluoSpheres for determining 
traction force, using CRISPR vector-infected cells and talin2-null cells as controls.  Scale bar, 30 
µm.  C. Quantitative constrained traction force.  Data are presented as mean ± SEM of 3 
experiments.  In each experiment, more than 30 cells from each group were analyzed.  t-test, 
*P<0.05, **P<0.01. 
Figure 6. Strong binding of talin2 to integrins is required for cell invasion.  A. Ablation of 
either talin1 or talin2 inhibited the invasion of U2 OS cells. B. Quantification of Experiment “A”. 
Data are presented as mean ± SEM from 3 independent experiments.  t-test, *P<0.05, 
**P<0.01.  C. Depletion of either talin1 or talin2 using shRNAs inhibited the invasion of MDA-
MB-231 cells.  Data are presented as mean ± SEM from 3 independent experiments.  t-test, 
**P<0.01, ***P<0.001.  D. Talin2-null U2 OS cells that express EGFP-talin2WT or –talin2S339C 
were examined for their Matrigel invasive capacities, using CRISPR vector-infected cells and 
talin2-null cells as controls. E. Quantification of Experiment “D”. Data are presented as mean ± 
SEM from 3 independent experiments.  t-test, *P<0.05.   
Figure 7.  Talin2 is indispensable for invadopodium-mediated matrix degradation.  A, B. 
Talin2 co-localized with cortactin (A) and Tks5 (B) at invadopodia in U2 OS cells plated on Cy3–
labeled gelatin for 16 h.  Cells were co-stained with a chicken anti-talin2 and a rabbit anti-
cortactin antibodies (A), or with an anti-talin2 and an anti-Tks5 (B) antibodies.  Representative 
TIRF images are showed.  Arrowheads point to mature invadopodia with co-localization of talin2 
and cortactin (A) or Tks5 (B).  Insets show magnified small invadopodia in the box. Scale Bars: 
20 µm.  Graphs show the mean degradation spots with cortactin (left bar) and with both 
cortactin and talin2 (right bar) (A), or with Tks5 (left bar) and with both Tks5 and talin2 (right bar) 
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(B).  Data are presented as mean ± SEM of 40 cells from 2 independent experiments.  C. Talin2 
co-localized with cortactin at invadopodia in MDA-MB-231 cells plated on Cy3–labeled gelatin 
for 10 h.  Scale Bars: 20 µm.  D. Ablation of either talin1 or talin2 inhibited invadopodium-
mediated matrix degradation.  Talin1- or talin2-null U2 OS cells were cultured on Alexa488-
gelatin immobilized on glass-bottom dishes, fixed and stained with Alexa647-phalloidin.  Scale 
bar, 20 µm.  E. Quantification of Experiment “D”.  Data are presented as mean ± SEM of 3 
independent experiments.  In each experiment, 20 cells from each group were analyzed.  t-test, 
*P < 0.05, **P<0.01.  F. Re-expression of full-length EGFP-talin2, but not -talin1, restored 
invadopodial matrix degradation in talin2-null cells.  Talin2-KO U2 OS cells were transiently 
transfected with full-length EGFP-talin1 or -talin2, and cultured on Cy3-gelatin immobilized on 
glass-bottom dishes, fixed and stained with Alexa647-phalloidin, using CRISPR vector-infected 
cells and talin2-KO cells as controls.  Scale bar, 20 µm.  G. Quantification of the invadopodia in 
experiment “F”.  Data are presented as mean ± SEM of 3 independent experiments.  t-test, 
*P<0.05.   
Figure 8. Strong binding of talin2 to β-integrin tails is indispensable for invadopodium-
mediated matrix degradation.   A. The distribution of traction force was co-localized with 
invadopodia.     US OS Cells were cultured on Alexa488-gelatin immobilized on acrylamide gel 
containing Red FluoSpheres.  Traction force and invadopodium formation were determined 
using an A1 confocal microscope.  Scale bar, 30 µm.  B. Quantification of the co-localization of 
traction force and invadopodia.  The gelatin degradation images were merged with traction force 
maps, and co-localization was examined manually.  Data are presented as mean ± SEM of 24 
cells from 3 independent experiments.    C-E. Stable expression of EGFP-talin2WT in talin2-null 
U2 OS cells restored invadopodial matrix degradation, but that of EGFP-talin2S339C did not.  C. 
Talin2-null U2 OS cells that stably express EGFP-talin2WT or –talin2S339C were cultured on Cy3-
gelatin immobilized on glass-bottom dishes, fixed and stained for talin2. Scale bar, 20 µm.  D. 
Quantitation of the assembly of talin2WT and talin2S339C to invadopodium-like structures.  Data 
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are presented as mean ± SEM of 3 independent experiments.  E. Quantitation of invadopodium 
area.  Data are presented as mean ± SEM of 3 independent experiments.  In each experiment, 
20 cells from each group were analyzed.  t-test, *P<0.05, **P<0.01. F-H. Talin2-null MDA-MB-
231 cells that express EGFP-talin2WT or –talin2S339C were cultured on Alexa Fluor 488-gelatin 
immobilized on glass-bottom dishes, fixed and stained with cortactin, using CRISPR vector-
infected cells and talin2-KO cells as controls.  F. Stable expression of EGFP-talin2WT and -
talin2S339C in talin2-null MDA-MB-231 cells using CRISPR.  G. Merged TIRF images of matrix 
degradation and cortactin staining. Scale bar, 20 µm.   H. Expression of EGFP-talin2WT in talin2-
null MDA-MB-231 cells restored invadopodial matrix degradation, but that of EGFP-talin2S339C 
did not. Data are presented as mean ± SEM of 3 independent experiments.  t-test, *P<0.05, 
**P<0.01, ***P<0.001.  I. A Proposed mechanism whereby talin2 regulates traction force 
generation, invadopodium-mediated matrix degradation and cancer cell invasion. 
 
 
 
 
 
 








